Full text 2026 Correction: Exploiting PRMT5 as a target for combination therapy in mantle cell lymphoma characterized by frequent ATM and TP53 mutations Che Y, Liu Y, Yao Y, et al. Bioinformatics Full text Loading PDF… Expand reader Download Abstract No abstract available.